Last reviewed · How we verify
dexter ketamine
Dexketamine (the active S-enantiomer of ketamine) blocks NMDA glutamate receptors in the central nervous system to produce rapid-acting antidepressant and anesthetic effects.
Dexketamine (the active S-enantiomer of ketamine) blocks NMDA glutamate receptors in the central nervous system to produce rapid-acting antidepressant and anesthetic effects. Used for Treatment-resistant depression, Anesthesia induction and maintenance.
At a glance
| Generic name | dexter ketamine |
|---|---|
| Also known as | ketamine plus |
| Sponsor | Federal University of São Paulo |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor (glutamate-gated ion channel) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Dexketamine is the S(+)-enantiomer of ketamine, which acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. This mechanism differs from traditional monoamine-based antidepressants and produces faster onset of action. The drug is used clinically for treatment-resistant depression and has anesthetic properties.
Approved indications
- Treatment-resistant depression
- Anesthesia induction and maintenance
Common side effects
- Dissociation
- Dizziness
- Nausea
- Sedation
- Increased blood pressure
Key clinical trials
- Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |